Skip to main content

Table 1 Assessment criteria for methodological quality of studies

From: The incidence of acute oxaliplatin-induced neuropathy and its impact on treatment in the first cycle: a systematic review

Study scoring criteria

Measures for outcome:

1. Assessment tool used for oxaliplatin-induced toxicity is described

2. A description of oxaliplatin administration given (regimen, dose modification criteria)

3. Acute neuropathy assessment is described

Study population:

4. A description of baseline variables at least two is included (age, sex, cancer, stage)

5. Inclusion and exclusion criteria are described

6. Time of acute oxaliplatin-induced toxicity measurement and number of patients assessed are described between the initiation of infusion and day 14.

7. Information is given about study subject selection process criteria

Study design:

8. The study sample size is described

9. The data is prospectively gathered

10. The process of data collection is described

Results:

11. Acute toxicities are described

12. The cycle at which acute toxicity occurred is described

13. The number of patients who needed prolonged infusion and/ or dose modification due to acute toxicity described.

14. The number of patients who needed treatment delay and/ or cessation due to acute toxicity reported.

  1. Criteria modified from [39]